The FDA alignment de-risks the Helix catheter's path to market and supports the broader CardiAMP program. Monitor the upcoming FDA CBER meeting and CardiAMP clinical readout in May 2026 for further catalysts. The stock may see near-term momentum, but the company's $12M market cap and lack of disclosed revenue warrant caution on sustained upside without fundamental progress.
Price Chart
Executive Summary
BioCardia announced FDA alignment on two regulatory pathways for its Helix Transendocardial Delivery Catheter System: simultaneous approval with the CardiAMP cell therapy system or a DeNovo pathway via a follow-on pre-submission. FDA raised no safety, performance, or compatibility concerns. This is a positive regulatory milestone but does not change the company's financial trajectory or near-term cash position.
Key Facts
- FDA agreed to two pathways for Helix marketing clearance: simultaneous with CardiAMP approval or via DeNovo pathway after a follow-on pre-submission.
- FDA raised no concerns on Helix safety data, device performance, or compatibility with general classes of agents.
- Upcoming catalysts in May 2026 include an FDA CBER meeting on CardiAMP approval pathways, a CardiAMP clinical readout at EuroPCR, and Japan PMDA formal clinical consultation advice.
- CardiAMP Cell Therapy has FDA Breakthrough designation; Japan PMDA indicated three completed clinical trials likely provide sufficient evidence for approval.
Financial Impact
No financial figures disclosed in the filing. The regulatory alignment has no immediate revenue or cost impact.
Risk Factors
- Helix approval is contingent on either CardiAMP approval or a separate DeNovo submission, both of which face regulatory and clinical uncertainty.
- BioCardia has a $12M market cap and no disclosed revenue; the company may need to raise additional capital to fund operations and regulatory activities.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-015753 |
| Exhibit: ex_959308.htm | 0001437749-26-015753 |
| Document: 0001437749-26-015753-index-headers.html | 0001437749-26-015753 |
| Document: 0001437749-26-015753-index.html | 0001437749-26-015753 |
| Document: 0001437749-26-015753.txt | 0001437749-26-015753 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9215 (+2.67%) |
Oct 19, 2026 8d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9215 (+2.39%) |
Oct 7, 2026 20d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9215 (−15.46%) |
Oct 1, 2026 26d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9215 (−9.66%) |
Oct 1, 2026 26d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9215 (−9.66%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9215 (−12.24%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9215 (−12.24%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9215 (−16.23%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9215 (−13.07%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9215 (−3.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers